Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GLAXO/TANABE JOINT VENTURE WILL BEGIN CEPHALOSPORIN CLINICAL TRIALS later this year on a new generation injectable product, Glaxo announced in a recent press release. The drug, for which trials are to be conducted in several countries, is for hospital use in the treatment of life-threatening infections. Glaxco said the companies, who announced the establishment of a joint venture on May 13, expect to win marketing approval in approximately two and a half years for the new cephalosporin, named TA 5901. The joint venture agreement is for the development and commercialization of the cephalosporin outside of Japan, and includes the U.S. market. Each company will have a 50% share in the new unit, Tanabe Glaxo. According to the press release, the drug will be marketed in Japan by Tanabe and Nippon Glaxo. The two companies originally announced their basic intent to cooperate over the compound in Oct. 1984. According to Glaxo, the clinical development work will be undertaken by Glaxo Group Research in association with Tanabe, and the basic manufacture will be undertaken by Glaxo Chem. Ltd. in the U.K.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts